Publications

1. GVS advice on liraglutide (Saxenda®) and naltrexon/ bupropion (Mysimba®) extension of further conditions

   The National Health Care Institute has completed its assessment whether the List 2 conditions for liraglutide (Saxenda®) and ...

   Report | 23-11-2022

2. GVS advice to include house dust mite extract 300 IR HDM (Actair®)

   The National Health Care Institute has completed its assessment whether house dust mite extract 300 IR HDM (Actair®) can be ...

   Report | 10-11-2022

3. Package advice pralsetinib (Gavreto®) for the treatment of non-small cell lung carcinoma (NSCLC)

   The National Health Care Insititue has completed its assessment whether pralsetinib (Gavreto®) can be included in the basic ...

   Report | 10-11-2022

4. Progress of the conditional inclusion process for rhPTH 1-84 (Natpar®)

   The National Health Care Institute advises the Director of Pharmaceuticals and Medical Technology at the Ministry of Health, ...

   Report | 02-11-2022

5. GVS advice nirmatrelvir/ritonavir (Paxlovid®) for the treatment of COVID-19

   The National Health Care Institute has assessed whether nirmatrelvir/ritonavir (Paxlovid®) can be included in the Medicine ...

   Report | 27-10-2022

6. GVS advice on natalizumab SC (Tysabri®) for adult patients with highly active RRMS

   The National Health Care Institute has completed its assessment whether natalizumab SC (Tysabri®) can be included in the Medicine ...

   Report | 25-10-2022

7. Package advice on ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsing and refractory multiple myeloma (RRMM)

   The National Health Care Institute advises the Minister not to include ciltacabtagene autoleucel (Carvykti®) for the treatment of ...

   Report | 20-10-2022

8. GVS advice to include the relugolix in combination with oestradiol and norethisteronacetate (Ryeqo®) combination

   The National Health Care Institute has completed its assessment whether relugolix in combination with oestradiol and ...

   Report | 19-10-2022

9. Evaluation and reassessment of further conditions for fampridine (Fampyra®)

   The National Health Care Institute advises the Minister that the fampridine (Fampyra®) conditions be revised and that the annual ...

   Report | 17-10-2022

10. Package advice atidarsagene autotemcel (Libmeldy®) for the treatment of metachromatic leukodystrophy (MLD)

    The National Health Care Institute advises the Minister to include atidarsagene autotemcel (Libmeldy®) in the basic health care ...

    Report | 27-09-2022